300147 香雪制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-7.281-18.384-20.184-21.3312.069
总资产报酬率 ROA (%)-1.649-4.597-5.295-5.9410.704
投入资产回报率 ROIC (%)-2.966-7.820-8.881-9.3841.017

边际利润分析
销售毛利率 (%)33.05034.34824.86926.27732.309
营业利润率 (%)-7.682-14.470-21.222-19.3666.573
息税前利润/营业总收入 (%)-0.360-6.414-13.687-14.1259.145
净利润/营业总收入 (%)-11.024-17.473-23.074-21.7743.765

收益指标分析
经营活动净收益/利润总额(%)77.47439.38575.91831.632120.697
价值变动净收益/利润总额(%)4.41312.318-9.244-7.91114.861
营业外收支净额/利润总额(%)27.20314.4589.3237.563-45.459

偿债能力分析
流动比率 (X)0.3620.3530.3240.4860.593
速动比率 (X)0.2730.2740.2340.3660.470
资产负债率 (%)72.98272.06568.52665.79465.782
带息债务/全部投入资本 (%)54.80753.75551.03254.57052.751
股东权益/带息债务 (%)73.93176.14986.17079.09284.716
股东权益/负债合计 (%)30.21232.25438.95340.44044.011
利息保障倍数 (X)-0.035-0.611-1.409-2.0701.977

营运能力分析
应收账款周转天数 (天)124.624102.156139.642129.415116.388
存货周转天数 (天)107.131104.740134.579131.612138.166